ContinenceOstomySource

Uroplasty, Inc. highlighted results from a clinical study of Macroplastique for the treatment of female stress urinary incontinence, now available in the January 2009 Journal of Urology. This is the first, large, multicenter randomized trial comparing the safety and efficacy of Macroplastique to another bulking agent used in the control group. In the Macroplastique group, the dry/cure rate was 36.9% versus 24.8% in the control group, with a 61.5% improvement compared to 48%, respectively. The authors conclude Macroplastique is a safe, effective, minimally invasive material that can be administered on an outpatient basis.

The U.S. Food and Drug Administration has approved a new drug to help patients suffering from overactive bladder ( OAB ). Toviaz ( fesoterodine fumarate ) works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate, and sudden urinary incontinence ( leakage of urine ), that are characteristic symptoms of OAB.

A paper published in the current issue of Reviews in Urology (2008; 10(2):85-91) concludes that urologists and other physicians treating benign prostatic hyperplasia (BPH) should prescribe medications that do not affect the heart's electrical activity (heart repolarization), especially since most men with BPH are older and often take other medications that also may impact the heart.

"The increasing productivity of our domestic sales team enabled us to expand our active Urgent PC customer base in the U.S. to 339, an increase from 166 customers during the comparable period a year ago. As doctors and their patients experience positive results with the Urgent PC, we are confident about our team's ability to continue to expand the active U.S. customer base as the fiscal year progresses."